The development of antibody-drug conjugates (ADCs) has significantly been advanced in
the past decade given the improvement of payloads, linkers and conjugation methods. In …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the target
specificity of an antibody with the potency of a chemotherapeutic. This therapeutic strategy …

Abstract Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal
antibodies with precise targeting and payloads with efficient killing, show great clinical …

The antibody–drug conjugate (ADC) field is in a transitional period. Older approaches to
conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but …

To facilitate subcutaneous dosing, biotherapeutics need to exhibit properties that enable
high-concentration formulation and long-term stability in the formulation buffer. For antibody …

Previous investigations on antibody-drug conjugate (ADC) stability have focused on drug
release by linker-deconjugation due to the relatively stable payloads such as maytansines …

Antibody–drug conjugates have attracted a great amount of attention as a therapeutic
strategy for diseases where targeting specific tissues and cells are critical components, such …

The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …

Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity
of a chemical agent. They represent a rapidly evolving area of oncology drug development …